---
title: "Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)"
description: "The purpose of the study is to evaluate the overall and disease free survival of recipients who have received G-CSF mobilized stem cells from HLA matched s"
url: "https://www.clareohealth.com/clinical-trials/NCT00185523"
---

The purpose of the study is to evaluate the overall and disease free survival of recipients who have received G-CSF mobilized stem cells from HLA matched sibling donors.

## Key Facts

**ID:** NCT00185523
**Status:** TERMINATED
**Type:** OBSERVATIONAL
**Enrollment:** 88
**Sponsor:** Stanford University

## About This Study

This clinical trial focused on using allogeneic peripheral blood stem cell transplantation to treat patients with certain types of leukemia, including acute myelogenous leukemia and chronic myelogenous leukemia. It was aimed at individuals who are in their first or second remission phase or chronic phase of their disease.

## Detailed Description

Allogeneic Peripheral Blood Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia in First Remission or Chronic Myelogenous Leukemia in First Chronic Phase

## Conditions

- Leukemia, Lymphocytic, Acute
- Leukemia
- Leukemia Acute Promyelocytic Leukemia (APL)
- Leukemia Acute Lymphoid Leukemia (ALL)
- Leukemia Chronic Myelogenous Leukemia (CML)
- Leukemia Acute Myeloid Leukemia (AML)
- Leukemia Chronic Lymphocytic Leukemia (CLL)

## Interventions

**PROCEDURE: Allogeneic hematopoietic cell transplantation**


## Eligibility

Inclusion Criteria:1.

## Who Can Participate

**Minimum age:** 0

**Maximum age:** 55

**Sex:** ALL

**Accepts healthy volunteers:** No

## Study Locations

- Stanford University School of Medicine, Stanford, California, United States

## Contact Information

## Important Dates

**Study start:** May 1, 2002

**Completion date:** April 1, 2009

**Last updated:** June 16, 2016

## Consider Discussing with Your Care Team

### Worth Discussing If

- You have acute myelogenous leukemia or chronic myelogenous leukemia and are in your first or second remission phase.
- You have a sibling who is a suitable donor with matching genetic markers.
- You are between the ages of 1 month and 55 years and are considering treatment options.

### Questions to Ask

- What are the potential benefits of participating in this trial compared to standard treatments?
- What are the risks and side effects associated with the stem cell transplantation?
- How will my eligibility be determined, and what tests will I need to undergo?
- What support will be available for me and my donor during the process?
- How long will the treatment and recovery process take?
- What happens if I experience complications during or after the transplant?

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT00185523)
